TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) – Stock analysts at Wedbush cut their Q3 2022 earnings estimates for shares of TCR2 Therapeutics in a research note issued to investors on Wednesday, September 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for TCR2 Therapeutics' current full-year earnings is ($3.19) per share. Wedbush also issued estimates for TCR2 Therapeutics' Q4 2022 earnings at ($0.37) EPS and FY2022 earnings at ($2.76) EPS.
Get TCR2 Therapeutics alerts:Several other research analysts have also commented on TCRR. Roth Capital restated a "buy" rating on shares of TCR2 Therapeutics in a report on Monday, August 8th. Truist Financial cut their price target on shares of TCR2 Therapeutics to $18.00 in a report on Tuesday, August 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.71.
TCR2 Therapeutics Trading Up 4.7 %
NASDAQ:TCRR opened at $1.80 on Monday. The firm has a market cap of $69.49 million, a price-to-earnings ratio of -0.60 and a beta of 1.79. TCR2 Therapeutics has a 12-month low of $1.60 and a 12-month high of $8.82. The company's 50-day moving average is $2.78 and its two-hundred day moving average is $2.69.TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.05).
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in TCR2 Therapeutics by 113.2% during the 1st quarter. GSA Capital Partners LLP now owns 158,593 shares of the company's stock valued at $438,000 after acquiring an additional 84,191 shares in the last quarter. Marquette Asset Management LLC increased its position in TCR2 Therapeutics by 20.7% in the 2nd quarter. Marquette Asset Management LLC now owns 40,163 shares of the company's stock worth $116,000 after buying an additional 6,901 shares during the period. Jane Street Group LLC bought a new position in TCR2 Therapeutics in the 2nd quarter worth approximately $38,000. Orion Portfolio Solutions LLC bought a new stake in shares of TCR2 Therapeutics during the second quarter valued at approximately $39,000. Finally, Acadian Asset Management LLC increased its position in shares of TCR2 Therapeutics by 3,250.7% during the first quarter. Acadian Asset Management LLC now owns 479,518 shares of the company's stock valued at $1,322,000 after purchasing an additional 465,207 shares during the period. 64.56% of the stock is owned by institutional investors and hedge funds.
About TCR2 Therapeutics
(Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.